InMed publishes study on cannabinol anti-inflammatory effects in skin diseases

InMed Pharmaceuticals Inc.

Study published in peer-reviewed journal Biofactors; sponsored by InMed and led by Dr. Maccarrone.
CBN prevented keratinocyte inflammation via TRPV1 and modulated endocannabinoid system enzymes.
CBN reduced pro-inflammatory cytokines (IL-8, IL-12, IL-31) and increased anti-inflammatory IL-10.
Potential applications for psoriasis, atopic dermatitis, and pruritus; supports cosmetic and therapeutic use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.